Company Name: |
ShangHai Biochempartner Co.,Ltd
|
Tel: |
17754423994 17754423994 |
Email: |
2853530910@QQ.com |
Products Intro: |
Product Name:ERD-308 CAS:2320561-35-9 Purity:98% HPLC LCMS Package:1G;100G
|
|
| ERD-308 Basic information |
| ERD-308 Chemical Properties |
Boiling point | 1173.0±65.0 °C(Predicted) | density | 1.271±0.06 g/cm3(Predicted) | storage temp. | 4°C, protect from light | solubility | DMSO:50.0(Max Conc. mg/mL);49.79(Max Conc. mM) | pka | 8.83±0.15(Predicted) | form | Solid | color | White to yellow |
| ERD-308 Usage And Synthesis |
Description | ERD-308 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER) ERD-308 achieves DC50_x000D_
(concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells. | in vitro | ERD-308 achieves DC50 (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells._x000D_
_x000D_
Reference: J Med Chem. 2019 Feb 14;62(3):1420-1442. https://pubmed.ncbi.nlm.nih.gov/30990042/ | target | ERD-308 is a highly potent PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. |
| ERD-308 Preparation Products And Raw materials |
|